HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EMA Specifies New Warnings For Codeine/Ibuprofen Combination Drugs

Executive Summary

A warning about the risk of severe hypokalemia and renal tubular acidosis is set to be added to the product information of fixed dose combinations of codeine and ibuprofen marketed in the EU following an investigation by the EMA's PRAC.

You may also be interested in...



Ireland Reviewing Codeine's OTC Status

Ireland’s drug regulator HPRA has initiated a formal regulatory procedure to determine if OTC remains the appropriate classification for codeine-containing products. The agency says the move is in response to a growing understanding of the potential impacts of addiction to codeine at low doses.

EMA Starts Safety Review Of Cough Drugs Containing Pholcodine

The European Medicines Agency is reviewing the safety of cough suppressants containing the opioid pholcodine after a French study found new evidence linking these products to an increased risk of anaphylactic reactions to drugs used in general anesthesia.  

'Purple Drank' Drug Cocktail Linked To France's Latest Reverse-Switch

Promethazine has been reverse-switched from OTC to prescription status in France, with rising abuse of the drug in the so-called Purple Drank cocktail one of the motivating factors for the move by the country's health ministry.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS153044

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel